Acción R5W STEM CELL THERAPEUTICS CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Stem Cell Therapeutics Corp. Xetra

Acciones

R5W

CA8585721001

Precio de cierre Xetra
Otros sitios de cotización
- EUR - Gráfico intradía de Stem Cell Therapeutics Corp.
2022 TCR2 Therapeutics nombra al Director de Negocios y Estrategia MT
2021 Pfizer busca mejorar su experiencia en enfermedades inmunoinflamatorias con la adquisición de Arena Pharmaceuticals por 6.700 millones de dólares MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
TCR2 Therapeutics Appoints Chief Business and Strategy Officer
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover
Pfizer schluckt kalifornische Biotechfirma für 6,7 Mrd Dollar
Pfizer scommette su promettente farmaco Arena con deal da 6,7 mld $
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index
Pfizer : a finalisé l'acquisition de Trillium Therapeutics
Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition
TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Trillium Therapeutics Inc. Announces Executive Changes
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.
TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)
Trillium: Q3 Earnings Snapshot
TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción TRIL
  4. Acción R5W
  5. Noticias Stem Cell Therapeutics Corp.
  6. Otros idiomas
marketscreener.com**derivados**es**/grafica-dinamica/**Premium**Expert**Access**Anual**Mensual**Como los expertos, acceda a todos los transcritos y descubra antes que nadie las mejores oportunidades.**#ffffff**/services/solutions/**#004eff**#000000**¡Desbloquéelos ya!**1**